## Marketa Skala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3032533/publications.pdf

Version: 2024-02-01

1040056 1281871 11 631 9 11 citations h-index g-index papers 11 11 11 993 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncology, The, 2019, 20, 494-503.	10.7	386
2	Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II). JAMA Oncology, 2021, 7, 1476.	7.1	50
3	The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART. Radiotherapy and Oncology, 2014, 111, 316-320.	0.6	42
4	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2018, 129, 377-386.	0.6	39
5	RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization. BMC Cancer, 2014, 14, 808.	2.6	35
6	DNA methylation changes following DNA damage in prostate cancer cells. Epigenetics, 2019, 14, 989-1002.	2.7	22
7	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2019, 140, 68-75.	0.6	20
8	Development of Indicators to Assess Quality of Care for Prostate Cancer. European Urology Focus, 2018, 4, 57-63.	3.1	17
9	Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand. JAMA Network Open, 2021, 4, e2129647.	5.9	13
10	Urban–rural prostate cancer disparities in a regional state of Australia. Scientific Reports, 2022, 12, 3022.	3.3	4
11	Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition. Prostate, 2022, 82, 540-550.	2.3	3